The large majority of drugs on the market today are small molecules and most are delivered orally. Small molecule drugs are part of what Syncona calls, the “First Wave” of technologies in healthcare and are dominated by large pharmaceutical companies.
Unless stated all financials at 31 March 2023
Value of portfolio
Syncona Board seats
New investments in the year